Optimizing the hit-to-lead process using SPR analysis

Assay and Drug Development Technologies

Volumn 2, Issue 4, 2004, Pages 407-415

  Löfås, Stefan ^a  

^a BIACORE AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

A 038; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; B 268; B 376; B7 ANTIGEN; CARBONATE DEHYDRATASE INHIBITOR; CD80 INHIBITOR; DRUG; INDINAVIR; LIPID; LIPOSOME; LOPINAVIR; NAPROXEN; NELFINAVIR; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PLASMA PROTEIN; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; PYRIMETHAMINE; QUININE; RITONAVIR; SAQUINAVIR; STREPTAVIDIN; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

BINDING AFFINITY; BIOSENSOR; DEGRADATION KINETICS; DRUG ADSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SPECIFICITY; DRUG TOXICITY; HUMAN; KINETICS; MEMBRANE PERMEABILITY; NONHUMAN; PREDICTION; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SURFACE PLASMON RESONANCE;

BIOSENSING TECHNIQUES; DRUG EVALUATION, PRECLINICAL; SURFACE PLASMON RESONANCE;

EID: 4644324195     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/1540658041850661     Document Type: Review

References (42)

1. Rich RL, Myszka DG: Advances in surface plasmon resonance biosensor analysis. Curr Opin Biotechnol 2000;11: 54-61.
2. Biacore Technology Note 1: Surface plasmon resonance. Biacore publications, BR-9001-15, 2001.
3. Biacore Technology: An introduction to surface plasmon resonance. Biacore publications, BR-9002-33, 2002.
4. McDonnell JM: Surface plasmon resonance: towards an understanding of the mechanisms of biological molecular recognition. Curr Opin Chem Biol 2001;5:572-577.
5. Baird CL, Courtenay ES, Myszka DG: Surface plasmon resonance characterization of drug/liposome interactions. Anal Biochem 2002;310:93-99.
6. Nakatani K, Sando S, Saito I: Scanning of guanine-guanine mismatches in DNA by synthetic ligands using surface plasmon resonance. Nat Biotechnol 2001;19: 51-55.
7. Wilson WD, Wang L, Tanious F, Kumar A: Biacore and DNA footprinting for discovery and development of new DNA targeted therapeutics and reagents. Biacore publications. Biacore Journal, 2001;1:15-19.
8. Nagata K, Handa H (eds): Real-Time Analysis of Biomolecular Interactions: Applications of BIACORE (English edition). Springer-Verlag, Tokyo, Japan, 2000.
9. Biacore Technology Note 15: Hydrodynamic addressing of detection spots in Biacore S51. Biacore publications, BR-9003-41, 2003.
10. Myszka DG, Rich RL: Implementing surface plasmon resonance biosensors in drug discovery. Pharm Sci Technol Today 2000;3:310-317.
11. Wong RL, Mytych D, Jacobs S, Bordens R, and Swanson SJ: Validation parameters for a novel biosensor assay which simultaneously measures serum concentrations of a humanized monoclonal antibody and detects induced antibodies. J Immunol Methods 1997;209:1-15.
12. Canziani G, Zhang W, Cines D, Rux A, Willis S, Cohen G, Eisenberg R, and Chaiken I: Exploring biomolecular recognition using optical biosensors. Methods 1999;19: 253-269.
13. Malmqvist M: BIACORE: an affinity biosensor system characterization of biomolecular interactions. Biochem Soc Trans 1999;27:335-340.
14. Rich RL, Myszka DG: Survey of the year 2000 commercial optical biosensor literature. J Mol Recognit 2001;14: 273-294.
15. Thurmond RL, Wadsworth SA, Schafer PH, Zivin RA, Siekierka JJ: Kinetics of small molecule inhibitor binding to p38 kinase. Eur J Biochem 2001;268:5747-5754.
16. Davis TM, Wilson WD: Determination of the refractive index increments of small molecules for correction of surface plasmon resonance data. Anal Biochem 2000;281:135-143.
17. Myszka DG: Analysis of small-molecule interactions using Biacore S51 technology. Anal Biochem 2004;329:316-323.
18. Chambers CA: The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001;22:217-223.
19. Debnam P, Huxley P, Matthews IR, da Graça Thrige D, Abery J: Screening lead CD80 inhibitors. Curr Drug Discovery Jan 2004;25-29.
20. SPR characterization of lead compounds against CD80: blocking T-cell activation in rheumatoid arthritis therapy. Biacore publications, Biacore Application Note 14, BR-9002-86, 2003.
21. Sadana A, Raju RR: Effect of chemical modification on enzyme activities and stabilities. In: Biocatalyst Design for Stability and Specificity. Himmel ME, Georgiou G (eds.), Chapter 24, p. 296. American Chemical Society, Washington, DC, 2000.
22. Berezov A, Zhang HT, Greene MI, Murali R: Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J Med Chem 2004;44:2565-2574.
23. Hämäläinen M, Markgren PO, Schaal W, Karlén A, Classon B, Vrang L, Samuelsson B, Hallberg A, Danielson UH. Characterization of a set of HIV-1 protease inhibitors using binding kinetics data from a biosensor-based screen. J Biomol Screen 2000;5:353-360.
24. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G: Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997;15:1271-1275.
25. Shuman CF, Hämäläinen MD, Danielson UH: Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. J Mol Recognit 2004;17:1-14.
26. Tomasselli AG, Heinrikson RL: Targeting the HIV-protease in AIDS therapy; a current clinical perspective. Biochim Biophys Acta 2000;1477:189-214.
27. Frisch C, Fersht AR, Schreiber G: Experimental assignment of the structure of the transition state for the association of barnase and barstar. J Mol Biol 2001;308: 69-77.
28. Myska DG: Kinetic, equilibrium, and thermodynamic analysis of macromolecular interactions with BIACORE. Methods Enzymol 2000;323:325-340.
29. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, Doyle ML: Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA 2000;97:9026-9031.
30. Hidalgo IJ: Assessing the absorption of new pharmaceuticals. Curr Top Med Chem 2001;1:385-401.
31. McWhirter A: Biacore S51 in predictive ADME studies. Biacore publications, Biacore Journal, vol. 3, no. 3, 2003.
32. Frostell-Karlsson A, Westerlund L, Widegren H: A Biacore-based assay for measuring the absorption of drugs to lipid membranes in early ADME studies. Biacore publications, Biacore Application Note 25, BR-9003-46, 2003.
33. Frostell-Karlsson Å, Widegren H, Palm M, Green CE, Hämäläinen MD, Westerlund L, Karlsson R, Fenner K, van de Waterbeemd H: Biosensor analysis of the interaction between drug compounds and liposomes of different properties; a 2-dimensional characterization tool for estimation of membrane absorption. J Pharm Sci (in press).
34. Nyberg S, Nordin H, Karlsson R, Hämäläinen MD: Characterization of drug-plasma protein interactions using surface plasmon resonance. Biacore publications, Biacore Application Note 30, BR-9002-99, 2002.
35. Frostell-Karlsson Å, Remaeus A, Roos H, Andersson K, Borg P, Hämäläinen M, Karlsson R: Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J Med Chem 2000;43:1986-1992.
36. Biacore Proof Statement: Quantitative structure activity relationship (QSAR) studies using Biacore. Biacore publications, BR-9003-15, 2003.
37. Markgren PO, Schaal W, Hämäläinen MD, Karlén A, Halberg A, Samuelsson B, Danielson UH: Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. J Med Chem 2002;45:5430-5439.
38. Andersson K, Choulier L, Hämäläinen MD, van Regenmortel MHV, Altschuh D, Malmqvist M: Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. J Mol Recognit 2001;14:62-71.
39. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA: In vivo activation of the p53 pathway by small molecule antagonists of MDM2. Science 2004;303: 844-848.
40. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000;408:307-310.
41. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
42. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumour suppressor transactivation domain. Science 1996;274:948-953.